PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-3.93%
Revenue decline while Drug Manufacturers - Specialty & Generic median is -1.33%. Seth Klarman would investigate if market share loss is temporary.
13.44%
Cost increase while Drug Manufacturers - Specialty & Generic shows cost reduction. Peter Lynch would examine competitive disadvantages.
-34.20%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 1.63%. Seth Klarman would investigate competitive position.
-31.50%
Margin decline while Drug Manufacturers - Specialty & Generic median is 1.66%. Seth Klarman would investigate competitive position.
-56.11%
R&D reduction while Drug Manufacturers - Specialty & Generic median is -13.72%. Seth Klarman would investigate competitive implications.
-15.19%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
-8.63%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
73.61%
Other expenses change of 73.61% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
-9.49%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is -1.89%. Seth Klarman would investigate advantages.
3.70%
Total costs growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
95.64%
Interest expense growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
6.19%
D&A growth while Drug Manufacturers - Specialty & Generic reduces D&A. Peter Lynch would examine asset strategy.
82.14%
EBITDA growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 17.50%. Joel Greenblatt would investigate advantages.
-14.41%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 5.57%. Seth Klarman would investigate causes.
61.81%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 12.98%. Joel Greenblatt would investigate advantages.
60.25%
Operating margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.79%. Joel Greenblatt would investigate advantages.
34.41%
Other expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.85%. Jim Chanos would check for issues.
56.49%
Pre-tax income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 22.73%. Joel Greenblatt would investigate advantages.
54.71%
Pre-tax margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 15.52%. Joel Greenblatt would investigate advantages.
-10.67%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is 18.40%. Seth Klarman would investigate advantages.
53.38%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 19.95%. Joel Greenblatt would investigate advantages.
51.47%
Net margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.20%. Joel Greenblatt would investigate advantages.
55.11%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 25.65%. Joel Greenblatt would investigate advantages.
55.11%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 26.69%. Joel Greenblatt would investigate advantages.
5.26%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.08%. Jim Chanos would check for issues.
5.26%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.08%. Jim Chanos would check for issues.